近期,Nature Metabolism杂志发表了新型双功能分子药物——GLP-1R激动与GIPR拮抗的共轭多肽药物AMG 133在肥胖患者中进行的一项随机双盲、安慰剂对照的I期临床试验[1](NCT04478708)令人鼓舞的研究结果(图1)。该研究为AMG 133的首次人体试验,分为单...
尽管GIPR拮抗剂或激动剂对体重减轻的分子和生理机制尚不清楚,对于同一目标,这两个方向如何在临床上发挥作用仍有待研究,但对于广大的超重/肥胖患者人群来讲,AMG 133的初步临床试验结果无疑是令人欣喜的。这也是以肠促胰素为代表的AOM研发的又一重要突破,AMG 133的研发不仅对临床减重治疗、糖尿病治疗和管理意义重大,而...
1. https://www.amgen.com/newsroom/press-releases/2022/12/amgen-presents-new-amg-133-phase-1-clinical-data-at-wcirdc-2022 2. Lu et al., 2021, Cell Reports Medicine 2, 100263,May 18, 2021 华人抗体协会是一个非营利、非政府的公益性组织,是第一...
接受最高剂量AMG 133治疗的患者在85天时体重平均降低14.5%(约26斤)。在这里值得一提的是,接受高剂量AMG 133治疗的患者,在停药150天后,仍然维持体重减轻超过11.2%,显示了AMG 133的持久疗效。 图4:AMG 133治疗后人体代谢和炎症指标变化情况 DOI: 10.1038/s42255-023-00966-w 而在药物安全性方面,AMG 133的安全...
2月 5 日,安进(Amgen)的研究人员在 Nature Metabolism 期刊发表了题为:A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings 的研究论文,文中表示,安进开发的双特异性分子 AMG 133 每 4 周一剂注射,在第 3 次注射后体...
AMG 133 is a First-in-Class InvestigationalBispecific Molecule That Activates GLP-1R and Inhibits GIPR Phase 1 Results Showed up to 14.5% Reduction in Body Weight at the Highest Dose After 12 Weeks Initiating Phase 2 Study in Early 2023 ...
[1]Amgen presents new AMG 133 phase 1 clinical data at WCIRDC 2022 . Retrieved Dec 1, 2022. From网页链接 [2]Amgen Business Review Meeting. Retrieved Fe 8, 2022, from网页链接 @药明康德内容团队报道 免责声明:药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的,文中观点不代...
Maridebartcafraglutide有望⽤于肥胖的研究[1][2]。REFERENCES[1].BloomgardenZT.The2023WCIRDC:Obesity[J].JournalofDiabetes,2024,16(4).[2].VéniantMM,etal.AGIPRantagonistconjugatedtoGLP-1analoguespromotesweightlosswithimprovedmetabolicparametersinpreclinicalandphase1settings.NatMetab.2024Feb;6(2):290-...
A new study has reported the phase I results of AMG 133 (also known as maridebart cafraglutide), which is a bispecific molecule consisting of a glucose-dependent insulinotropic peptide receptor (GIPR) antagonist antibody conjugated to two glucagon-like peptide 1 (GLP1) agonists. The researchers...
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation https://clinicaltrials.gov/ct2/show/NCT03600883 (2018). Gentile, D. R. et al. Ras binder induces a modified switch-II Pocket in GTP and ...